Italia markets closed

OPKO Health, Inc. (0KCS.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
1,9200-0,0200 (-1,03%)
Alla chiusura: 06:48PM BST
Schermo intero
Chiusura precedente1,9400
Denaro0,0000 x N/D
Lettera0,0000 x N/D
Min-Max giorno1,9200 - 1,9400
Intervallo di 52 settimane1,9200 - 1,9400
Media VolumeN/D
Beta (5 anni mensile)1,75
Rapporto PE (ttm)N/D
EPS (ttm)-0,1790
Prossima data utili26 ott 2022 - 31 ott 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Jon Cohen and Michael Hansen Join Talkspace’s Board of Directors

    Shareholders Approve All Measures at First Annual Meeting of StockholdersNEW YORK, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Shareholders of Talkspace, Inc. (Nasdaq: TALK) today elected Jon Cohen, M.D., to the virtual behavioral healthcare company’s board of directors and approved all other shareholder proposals during the company’s first Annual Meeting of Stockholders. Dr. Cohen is prior Executive Chairman and Chief Executive Officer of BioReference Laboratories and Senior Vice President of OPKO Healt

  • GlobeNewswire

    OPKO Health Announces Leadership Changes for BioReference Laboratories

    MIAMI, Aug. 16, 2022 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK), a multinational biopharmaceutical and diagnostics company, today announced that Jon R. Cohen, M.D., is retiring from his role as Executive Chairman and Chief Executive Officer of BioReference Laboratories and Senior Vice President and a Director of OPKO. He will remain as an employed advisor to the company through the end of December 2022 and continue as a consultant for the following nine months to assist in positioning t

  • GlobeNewswire

    OPKO Health Reports 2022 Second Quarter Business Highlights and Financial Results

    Conference call begins at 4:30 p.m. Eastern time todayMIAMI, Aug. 04, 2022 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six months ended June 30, 2022. Business highlights for the second quarter of 2022 and subsequent weeks include the following: Acquired ModeX Therapeutics, Inc. (ModeX), gained proprietary immunotherapy technology, seasoned scientific team, new executives and Directors. ModeX is focused on developing uni